Daewoong wins Albis patent dispute

Published: 2009-04-07 06:57:00
Updated: 2009-04-07 06:57:00
Daewoong Pharm is expected to achieve more stable revenue in the sale of Albis, a ranitidine product plus bismuth and sucralfate, by winning its patent dispute.

The Korean Intellectual Property Tribunal ruled on March 31 that the controversial process patent of Albis should be patentable in t...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.